Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2
Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and ...
Sarepta Therapeutics (SRPT) Gets a Hold from RBC Capital
RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) on April 3 and set a price target ...
pharmaphorum21h
FDA experts to vote on Spark's groundbreaking gene therapy
Advisers to the US regulator will meet today to discuss Spark Therapeutics' Luxturna, which could become the first gene therapy approved for an inherited disease in the US. However concerns about ...